LIVMARLI is the first and only treatment available for cholestatic pruritus in patients with Alagille syndrome and ...

The impressive growth of cholestatic pruritus market from $19.20 billion in 2024 to an estimated $20.28 billion in 2025. This rapid growth is fuelled by augmenting prevalence of skin disorders ...

LIVMARLI is the first and only treatment available for cholestatic pruritus in patients with Alagille syndrome and Progressive Familial Intrahepatic Cholestasis in Japan Mirum Pharmaceuticals ...

Mirum Pharmaceuticals (MIRM) announced that its partner, Takeda (TAK), has received approval by the Japanese Ministry of Health, Labour, and ...

Mirum Pharmaceuticals stock surged 25% and how LIVMARLI drives growth. Explore future prospects with Volixibat. Click here to ...

Its flagship product, Livmarli (maralixibat), is approved for treating cholestatic pruritus in pediatric ALGS patients, contributing to the company’s revenue. Vivet Therapeutics collaborates ...

This medication is now the first and only approved treatment for cholestatic pruritus associated with Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC) in Japan.

Mirum Pharmaceuticals’ MIRM lead product, Livmarli (maralixibat), an orally administered ileal bile acid transporter (“IBAT”) ...

Drug-induced liver injury (DILI) is a significant concern in clinical practice, arising from medications, herbs, and dietary ...

Mirum is evaluating Livmarli in the phase III EXPAND study for treating pruritus in rare cholestatic conditions. Enrollment in the study is expected to be completed in 2026. Mirum acquired Travere ...